A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX)

Kentaro Igarashi; Kei Kawaguchi; Takashi Murakami; Tasuku Kiyuna; Kentaro Miyake; Norio Yamamoto; Katsuhiro Hayashi; Hiroaki Kimura; Scott D. Nelson; Sarah M. Dry; Yunfeng Li; Arun S. Singh; Shinji Miwa; Akira Odani; Fritz C. Eilber; Hiroyuki Tsuchiya; Robert M. Hoffman

doi:10.18632/oncotarget.18806

A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX)

Kentaro Igarashi, Kei Kawaguchi, Takashi Murakami, Tasuku Kiyuna, Kentaro Miyake, Norio Yamamoto, Katsuhiro Hayashi, Hiroaki Kimura, Scott D. Nelson, Sarah M. Dry, Yunfeng Li, Arun S. Singh, Shinji Miwa, Akira Odani, Fritz C. Eilber, Hiroyuki Tsuchiya, Robert M. Hoffman

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

A patient high-grade undifferentiated pleomorphic soft-tissue sarcoma (UPS) from a striated muscle was previously orthotopically implanted in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) nudemouse model. In the present study, two weeks after orthotopic transplantation of the UPS, mice were treated intraperitoneally with cisplatinum (CDDP), doxorubicin (DOX) or a novel anionic-phosphate-platinum compound 3Pt. Treatments were repeated weekly for a total of 3 times. Six weeks after transplantation, all mice were sacrificed and evaluated. After two weeks treatment, tumor sizes were as follows: control (G1): 2208.3 mm³; CDDP (G2): 841.8±3 mm³, p=0.0001; DOX (G3): 693.1±3 mm³, p=6.56E-7; 3Pt (G4): 333.7±1 mm³, p=4.8E-8. 3Pt showed significantly more efficacy compared to other therapy drugs tested: CDDP (p=0.0002), DOX (p=0.001). There were no animal deaths in any of the four groups. The present results suggest 3Pt is a promising new candidate for UPS since it was demonstrated to be effective in a PDOX model.

Original language	English
Pages (from-to)	63353-63359
Number of pages	7
Journal	Oncotarget
Volume	8
Issue number	38
DOIs	https://doi.org/10.18632/oncotarget.18806
Publication status	Published - 2017
Externally published	Yes

Keywords

3Pt
Efficacy
PDOX
Platinum complex
Undifferentiated pleomorphic sarcoma

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.18806

Cite this

Igarashi, K., Kawaguchi, K., Murakami, T., Kiyuna, T., Miyake, K., Yamamoto, N., Hayashi, K., Kimura, H., Nelson, S. D., Dry, S. M., Li, Y., Singh, A. S., Miwa, S., Odani, A., Eilber, F. C., Tsuchiya, H., & Hoffman, R. M. (2017). A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX). Oncotarget, 8(38), 63353-63359. https://doi.org/10.18632/oncotarget.18806

A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX). / Igarashi, Kentaro; Kawaguchi, Kei; Murakami, Takashi et al.

In: Oncotarget, Vol. 8, No. 38, 2017, p. 63353-63359.

Research output: Contribution to journal › Article › peer-review

Igarashi, K, Kawaguchi, K, Murakami, T, Kiyuna, T, Miyake, K, Yamamoto, N, Hayashi, K, Kimura, H, Nelson, SD, Dry, SM, Li, Y, Singh, AS, Miwa, S, Odani, A, Eilber, FC, Tsuchiya, H & Hoffman, RM 2017, 'A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX)', Oncotarget, vol. 8, no. 38, pp. 63353-63359. https://doi.org/10.18632/oncotarget.18806

@article{e9113c4747ff400a9d8bf10f515df535,

title = "A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX)",

abstract = "A patient high-grade undifferentiated pleomorphic soft-tissue sarcoma (UPS) from a striated muscle was previously orthotopically implanted in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) nudemouse model. In the present study, two weeks after orthotopic transplantation of the UPS, mice were treated intraperitoneally with cisplatinum (CDDP), doxorubicin (DOX) or a novel anionic-phosphate-platinum compound 3Pt. Treatments were repeated weekly for a total of 3 times. Six weeks after transplantation, all mice were sacrificed and evaluated. After two weeks treatment, tumor sizes were as follows: control (G1): 2208.3 mm3; CDDP (G2): 841.8±3 mm3, p=0.0001; DOX (G3): 693.1±3 mm3, p=6.56E-7; 3Pt (G4): 333.7±1 mm3, p=4.8E-8. 3Pt showed significantly more efficacy compared to other therapy drugs tested: CDDP (p=0.0002), DOX (p=0.001). There were no animal deaths in any of the four groups. The present results suggest 3Pt is a promising new candidate for UPS since it was demonstrated to be effective in a PDOX model.",

keywords = "3Pt, Efficacy, PDOX, Platinum complex, Undifferentiated pleomorphic sarcoma",

author = "Kentaro Igarashi and Kei Kawaguchi and Takashi Murakami and Tasuku Kiyuna and Kentaro Miyake and Norio Yamamoto and Katsuhiro Hayashi and Hiroaki Kimura and Nelson, {Scott D.} and Dry, {Sarah M.} and Yunfeng Li and Singh, {Arun S.} and Shinji Miwa and Akira Odani and Eilber, {Fritz C.} and Hiroyuki Tsuchiya and Hoffman, {Robert M.}",

note = "Publisher Copyright: {\textcopyright} Igarashi et al.",

year = "2017",

doi = "10.18632/oncotarget.18806",

language = "English",

volume = "8",

pages = "63353--63359",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "38",

}

TY - JOUR

T1 - A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX)

AU - Igarashi, Kentaro

AU - Kawaguchi, Kei

AU - Murakami, Takashi

AU - Kiyuna, Tasuku

AU - Miyake, Kentaro

AU - Yamamoto, Norio

AU - Hayashi, Katsuhiro

AU - Kimura, Hiroaki

AU - Nelson, Scott D.

AU - Dry, Sarah M.

AU - Li, Yunfeng

AU - Singh, Arun S.

AU - Miwa, Shinji

AU - Odani, Akira

AU - Eilber, Fritz C.

AU - Tsuchiya, Hiroyuki

AU - Hoffman, Robert M.

PY - 2017

Y1 - 2017

N2 - A patient high-grade undifferentiated pleomorphic soft-tissue sarcoma (UPS) from a striated muscle was previously orthotopically implanted in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) nudemouse model. In the present study, two weeks after orthotopic transplantation of the UPS, mice were treated intraperitoneally with cisplatinum (CDDP), doxorubicin (DOX) or a novel anionic-phosphate-platinum compound 3Pt. Treatments were repeated weekly for a total of 3 times. Six weeks after transplantation, all mice were sacrificed and evaluated. After two weeks treatment, tumor sizes were as follows: control (G1): 2208.3 mm3; CDDP (G2): 841.8±3 mm3, p=0.0001; DOX (G3): 693.1±3 mm3, p=6.56E-7; 3Pt (G4): 333.7±1 mm3, p=4.8E-8. 3Pt showed significantly more efficacy compared to other therapy drugs tested: CDDP (p=0.0002), DOX (p=0.001). There were no animal deaths in any of the four groups. The present results suggest 3Pt is a promising new candidate for UPS since it was demonstrated to be effective in a PDOX model.

AB - A patient high-grade undifferentiated pleomorphic soft-tissue sarcoma (UPS) from a striated muscle was previously orthotopically implanted in the right biceps femoris muscle of nude mice to establish a patient-derived orthotopic xenograft (PDOX) nudemouse model. In the present study, two weeks after orthotopic transplantation of the UPS, mice were treated intraperitoneally with cisplatinum (CDDP), doxorubicin (DOX) or a novel anionic-phosphate-platinum compound 3Pt. Treatments were repeated weekly for a total of 3 times. Six weeks after transplantation, all mice were sacrificed and evaluated. After two weeks treatment, tumor sizes were as follows: control (G1): 2208.3 mm3; CDDP (G2): 841.8±3 mm3, p=0.0001; DOX (G3): 693.1±3 mm3, p=6.56E-7; 3Pt (G4): 333.7±1 mm3, p=4.8E-8. 3Pt showed significantly more efficacy compared to other therapy drugs tested: CDDP (p=0.0002), DOX (p=0.001). There were no animal deaths in any of the four groups. The present results suggest 3Pt is a promising new candidate for UPS since it was demonstrated to be effective in a PDOX model.

KW - 3Pt

KW - Efficacy

KW - PDOX

KW - Platinum complex

KW - Undifferentiated pleomorphic sarcoma

UR - http://www.scopus.com/inward/record.url?scp=85029806471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029806471&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.18806

DO - 10.18632/oncotarget.18806

M3 - Article

AN - SCOPUS:85029806471

SN - 1949-2553

VL - 8

SP - 63353

EP - 63359

JO - Oncotarget

JF - Oncotarget

IS - 38

ER -

A novel anionic-phosphate-platinum complex effectively targets an undifferentiated pleomorphic sarcoma better than cisplatinum and doxorubicin in a patient-derived orthotopic xenograft (PDOX)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this